Clearstead Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
CCMG
Clearstead Advisors's XPH Position: Q2 2022 in Review
Clearstead Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2022, closing a stake of 26 shares — an estimated $1K sold.
Clearstead Advisors first reported a position in XPH in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 71 funds tracked by Wall St. Rank hold XPH as of Q2 2022.
- Clearstead Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2022 after selling out during the quarter.
- Clearstead Advisors sold 26 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2022, an estimated $1K.
- Clearstead Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2022 and held it in 1 quarter.
- Clearstead Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1K in Q1 2022.
- 71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2022.
Based on Clearstead Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.